Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and ...

Exelixis is making solid progress toward that goal. Late last year, it submitted an application to the U.S. Food and Drug ...

Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.

A proposed model illustrating how tumor cells release PD-L1-containing small extracellular vesicles (sEVs) that suppress ...